Immune Thrombocytopenic Purpura, ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Warm Autoimmune Hemolytic Anemia (WAIHA)
Conditions
Keywords
CD19, CTX112, Zugocabtagene geleucel, zugo-cel, CAR-T, ITP, warm autoimmune hemolytic anemia, wAIHA, Immune Thrombocytopenic Purpura, Immune Thrombocytopenia
Brief summary
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleucel (zugo-cel) in adult participants with relapsed/refractory primary Immune Thrombocytopenia (ITP) and relapsed/refractory primary Warm Autoimmune Hemolytic Anemia (wAIHA).
Detailed description
This trial will assess the safety and preliminary efficacy of CTX112 or Zugocabtagene geleucel (zugo-cel) in adults with relapsed or refractory hematologic autoimmune diseases (AID), including primary ITP and primary wAIHA. In these B-cell-mediated conditions, autoantibodies target platelets (ITP) or red blood cells (wAIHA), causing severe thrombocytopenia or anemia. Although several treatments exist, some patients relapse or remain refractory, resulting in significant morbidity, mortality, and reduced quality of life. This underscores the need for new therapeutic options. B-cell-directed therapies are central to current management, and emerging data show promising activity of anti-CD19 CAR T cell therapies in AID. CTX112 (zugo-cel) is an allogeneic, CD19-targeted CAR T cell product derived from healthy donors and genetically modified ex vivo using CRISPR-Cas9. Similar to autologous CD19 CAR T therapies, CTX112 (zugo-cel) may induce clinical responses after a single treatment and offers the advantages of off-the-shelf availability. Up to 60 participants may be enrolled. Study duration will be up to 5 years.
Interventions
BIOLOGICALCTX112
CTX112 (zugo-cel): CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components
Sponsors
CRISPR Therapeutics AG
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥18 years. 2. Participants must voluntarily sign a written informed consent and be willing and able to comply with all trial requirements. 3. Adequate hematologic, renal, liver, cardiac and pulmonary function. 4. Participants must agree to use acceptable methods of contraception. 5. Willing and able to comply with scheduled visits, treatment plan, laboratory tests, contraceptive guidelines, and other trial procedures. 6. Diagnosis of relapsed/refractory primary Immune Thrombocytopenic Purpura (ITP) or Warm Autoimmune Hemolytic Anemia (WAIHA)
Exclusion criteria
1. Prior treatment with anti-CD19 therapy or any gene therapy or genetically modified cell therapy. 2. Prior solid organ (e.g., heart, liver, kidney, lung) transplant or hematopoietic cell transplant. 3. Severe active or history of central nervous (CNS) involvement. 4. Presence of other active autoimmune disease or other conditions that are likely to pose increased safety risks and/or confound disease assessments, or pose significant risk to those receiving CAR T cell therapy. 5. History of primary or secondary immunodeficiency. 6. Presence or history of certain bacterial, viral or fungal infection 7. Malignancy in the last 5 years (with the exception of cancers deemed to be low likelihood for recurrence). 8. Diagnosis of a genetic disorder associated with bone marrow failure or myelodysplastic syndrome. 9. History or current diagnosis that requires uninterrupted, ongoing anticoagulation. 10. Pregnant or lactating. 11. Presence or history of disease requiring treatment that is not compatible with the study protocol; presence or history of other conditions that are not compatible with the study protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the safety of CTX112 in adult participants with refractory hematologic autoimmune diseases, including ITP or wAIHA. | From CTX112 infusion up to 28 days post infusion. | Incidence of dose-limiting toxicities. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To assess the pharmacodynamics response to CTX112 in adult participants with ITP or wAIHA. | From CTX112 infusion up to 60 months post-infusion | Change from baseline in B cell levels |
| To assess the pharmacokinetics (PK) of CTX112 in adult participants with ITP or wAIHA. | From CTX112 infusion up to 60 months post-infusion. | Levels of CTX112 in blood over time. |
| To assess the preliminary efficacy of CTX112 in adult participants with ITP or wAIHA. | From CTX112 infusion up to 60 months post-infusion | For participants with ITP, platelet response. For participants with wAIHA, hemoglobin response. |
Countries
Germany, Spain, United States
Contacts
CONTACTClinical Trials
Outcome results
None listed